Volume 4 Supplement 1

Association for Immunotherapy of Cancer: Cancer Immunotherapy – 2nd Annual Meeting

Open Access

Transitory response to vaccination with PSCA-/PSA-peptide loaded, autologous dendritic cells in patients with metastatic, hormone-refractory prostate cancer

  • AK Kaskel1Email author,
  • R Zeiser1,
  • R Jochim1,
  • W Schultze-Seemann2,
  • CF Waller1 and
  • H Veelken1
Cancer Cell International20044(Suppl 1):S16

https://doi.org/10.1186/1475-2867-4-S1-S16

Received: 28 April 2004

Published: 1 July 2004

Clinical trials employing vaccination with prostate-specific membrane antigen (PSMA) loaded dendritic cells (DC) in patients (pts) with advanced prostate cancer yielded response rates of >30%. We decided for HLA-A2 restricted peptides derived from prostate stem cell antigen (PSCA) and prostate specific antigen (PSA 1–3) because both antigens are overexpressed in >85% of prostate cancer and were demonstrated to induce antigen specific T-cell responses in vitro. Cell penetrating peptide (CPP) is a peptide derived from the HIV-tat protein that prolongs antigen presentation in vitro leading to enhanced antitumor immunity in vivo. Therefore, half of the pts were assigned to receive CPP-PSCA loaded DCs. The purpose of this study is to assess feasibility, patient safety, PSCA-/PSA-specific T-cell responses and tumor regression in vivo. Pts were vaccinated s.c. in 14d intervals. Response was assessed two weeks after the 4th vaccination. Delayed-type hypersensitivity (DTH) was tested d4+d46. Immune competence was monitored by HBV vaccination d1+d43. So far, 9/12 planned pts completed vaccination. No toxicities were observed. 5/9 pts achieved SD (3 with <50% decrease, 2 with <50% increase in PSA) and 3 of these but no non-responders developed a positive DTH after the 4th vaccination. The addition of CPP did not correlate with outcome. Responding pts received at mean two further vaccinations 4 weeks apart. At a median follow-up of 8.6 months 70% of pts are alive compared to a reported OS of 59% and 28% at a follow-up of 6 and 11 months, respectively for pts with metastatic, hormone-refractory disease [13]. No peptide specific T-cells were detected in two pts evaluated so far, however, the correlation of clinical and DTH responses suggests a tumor specific immunity. Our data indicate that vaccination with PSA/PSCA-peptide-loaded, autologous DCs is safe and well tolerated. Vaccination of more patients, long-term follow-up and completion of immune monitoring are needed to evaluate anti tumor effects.

Authors’ Affiliations

(1)
Department of Hematology/Oncology, Freiburg University Medical Center
(2)
Department of Urology, Freiburg University Medical Center

References

  1. Fossa SD: Br J Urol. 1992, 69: 175-179.View ArticlePubMedGoogle Scholar
  2. Kelly WK: J Clin Oncol. 1993, 11: 607-615.PubMedGoogle Scholar
  3. Smaletz O: J Clin Oncol. 2002, 20: 3972-3982. 10.1200/JCO.2002.11.021.View ArticlePubMedGoogle Scholar

Copyright

© Author(s); licensee BioMed Central Ltd. 2004

Advertisement